MediciNova Inc. (NASDAQ:MNOV) and Harpoon Therapeutics Inc. (NASDAQ:HARP), both competing one another are Biotechnology companies. We will contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova Inc.	N/A	0.00	14.68M	-0.36	0.00
Harpoon Therapeutics Inc.	4.75M	65.23	27.37M	-0.94	0.00

Table 1 shows the gross revenue, earnings per share and valuation for MediciNova Inc. and Harpoon Therapeutics Inc.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
MediciNova Inc.	0.00%	-19.7%	-18.8%
Harpoon Therapeutics Inc.	-576.21%	0%	0%

Liquidity

MediciNova Inc.’s Current Ratio is 28.6 while its Quick Ratio is 28.6. On the competitive side is, Harpoon Therapeutics Inc. which has a 3.8 Current Ratio and a 3.8 Quick Ratio. MediciNova Inc. is better positioned to pay off short and long-term obligations compared to Harpoon Therapeutics Inc.

Analyst Ratings

Ratings and Recommendations for MediciNova Inc. and Harpoon Therapeutics Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
MediciNova Inc.	0	0	1	3.00
Harpoon Therapeutics Inc.	0	0	2	3.00

MediciNova Inc.’s upside potential currently stands at 112.36% and an $22 consensus price target. Harpoon Therapeutics Inc. on the other hand boasts of a $23.5 consensus price target and a 84.60% potential upside. Based on the analysts belief we can conclude, MediciNova Inc. is looking more favorable than Harpoon Therapeutics Inc.

Institutional and Insider Ownership

The shares of both MediciNova Inc. and Harpoon Therapeutics Inc. are owned by institutional investors at 26.5% and 35.2% respectively. About 2.2% of MediciNova Inc.’s share are held by insiders. Comparatively, 0.5% are Harpoon Therapeutics Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
MediciNova Inc.	1.76%	-4.74%	-16.43%	-24.91%	-19.98%	5.88%
Harpoon Therapeutics Inc.	18.45%	0%	0%	0%	0%	26%

For the past year MediciNova Inc.’s stock price has smaller growth than Harpoon Therapeutics Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company’s product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.